NathanBaharyMDPhD

Oncology • Pittsburgh, PA

Gastrointestinal Cancer

Academic Chief of Medical Oncology—AHN Cancer Institute Director of AHNCI Research

Join to view full profile

Dr. Bahary is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bahary's full profile

Already have an account?

Office
320 East North Avenue
Room O242H
Pittsburgh, PA 15212
Phone+1 412-359-6391

Summary

Dr. Nathan Bahary is an oncologist in Pittsburgh, PA. He received his medical degree from Weill Cornell Medicine and has been in practice 28 years. He specializes in gastrointestinal cancer and is experienced in gastrointestinal oncology, general medical oncology, and pancreatic neoplasms.

Education & Training

Dana-Farber Cancer InstitutePost-Doctoral Fellowship, 1997 - 2002
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1998
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
Rockefeller UniversityPhD, Molecular Genetics, 1987 - 1992
Weill Cornell MedicineClass of 1989

Certifications & Licensure

NY State Medical License 2022 - 2026
OH State Medical License 2022 - 2026
WV State Medical License 2022 - 2026
PA State Medical License 2002 - 2024
MA State Medical License 1994 - 2003
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers Start of enrollment: 2005 Apr 01
Terminated
Phase 2
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 2
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy Start of enrollment: 2006 Jun 01
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 1
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma Start of enrollment: 2011 Jul 25
Completed
Phase 2
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients Start of enrollment: 2011 Nov 01
Terminated
Phase 2
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Supportive Care Intervention-Pancreas Start of enrollment: 2013 Jul 01
Completed
Not Applicable
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12
Completed
Phase 2
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer Start of enrollment: 2017 Dec 13
Terminated
Phase 2
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) Start of enrollment: 2020 Jun 23
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer Start of enrollment: 2023 Jun 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

4430 citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante
The New England Journal of Medicine. 2013-10-30
1188 citations
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Benjamin J. Raphael, Ralph H. Hruban, Andrew J. Aguirre, Richard A. Moffitt, Jen Jen Yeh
Cancer Cell. 2017-08-14
215 citations
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Bi...
Aatur D. Singhi, Ben George, Joel R. Greenbowe, Jon Chung, James Suh
Gastroenterology. 2019-06-01

Lectures

Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

National Drug Shortage Impacting Cancer Care at UPMCMay 25th, 2023
Despite Challenging Statistics, ‘Jeopardy!’ Host Alex Trebek Vows to Fight Pancreatic CancerMarch 7th, 2019
Genomics Could Better Match Treatments to Pancreatic Cancer PatientsMarch 4th, 2019
Join now to see all